Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2024-12-17 Earnings Release
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
Earnings Release 2024
Earnings Release Classification · 99% confidence The document is titled "COMPANY ANNOUNCEMENT" and is marked as "Inside information." It announces a reorganization of the marketing and sales department and, critically, revises the financial guidance for 2024 (revenue and EBIT expectations). This type of announcement, which provides key financial updates outside of a full quarterly or annual report, aligns best with an Earnings Release (ER), which covers initial announcements of periodical financial results and key highlights. It is too specific for a general Regulatory Filing (RNS) and does not fit the definitions for a full report (10-K, IR), a management discussion (MDA), or a capital event (CAP). The short length (2505 chars) and focus on revised guidance strongly suggest an ER. FY 2024
2024-12-17 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is titled "Skema til underretning ved udsættelse af offentliggørelse af intern viden" (Template for notification regarding postponement of disclosure of inside information). It details the identity of the issuer (ViroGates A/S), the person submitting the notification, and specifically describes the inside information whose disclosure was delayed (a reorganization) versus information disclosed immediately (revised guidance). This structure strongly suggests a regulatory filing related to the handling and timing of inside information disclosure, which is a mandatory requirement under market abuse regulations (like MAR in the EU). Since this is a specific regulatory notification about market information handling, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate general category for miscellaneous regulatory announcements that don't fit elsewhere is Regulatory Filings (RNS). The document length is short (1304 chars), but it is the report itself, not an announcement *of* a report, so RPA is less suitable than RNS for this specific type of regulatory disclosure.
2024-12-17 Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a standard regulatory form (Finanstilsynet) used for reporting transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (Lars Krogsgaard, Board Member), the issuer (ViroGates A/S), the nature of the transaction (Køb/Purchase of shares), and the transaction details. This falls under the category of Director's Dealing.
2023-12-21 Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a standard regulatory form (Finanstilsynet) used for reporting transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (Jakob Knudsen, CEO), the issuer (ViroGates A/S), the nature of the transaction (Køb/Purchase of shares), and the transaction details. This falls under the category of Director's Dealing (DIRS).
2023-12-21 Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by persons discharging managerial responsibilities (PDMRs), specifically the CEO and a board member, as required by the EU Market Abuse Regulation (MAR) Article 19. The text explicitly details the purchase of shares by these individuals. This falls directly under the definition of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2023-12-21 English
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification of transactions by persons discharging managerial responsibilities (PDMR) under the EU Market Abuse Regulation (MAR) Article 19. It details specific share acquisitions by the CEO and a board member. While it mentions the 'Managers' transactions' category, the specific nature of reporting insider/director share dealings aligns perfectly with the 'Director's Dealing' (DIRS) classification.
2023-12-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.